Julie R. Gralow, MD
Professor, Medical Oncology
Department of Medicine
Division of Oncology
Director, Breast Medical Oncology
Associate Member, Fred Hutchinson Cancer Research Center, Clinical Research Division
Seattle Cancer Care Alliance
825 Eastlake Ave E G3-630
Seattle, WA 98109-1023
McKenze Sigler / Ben Thompson
206.288.6261 / 206.288.2054
Specialty / Expertise
- Investigational breast cancer treatment
- Bone metastases
Current Research Projects
- Trial of Adjuvant Bisphosphonates for Prevention of Bone Metastases in Early Stage Breast Cancer
- Trial of Celecoxib for Breast Cancer Chemoprevention
- Study Investigating Barrier to Accrual to Clinical Trials
Dr. Gralow received her undergraduate degree from Stanford University, Palo Alto, CA and her MD from University of Southern California, Los Angeles, CA. She completed her Internal Medicine Residency at the Harvard Medical School's Brigham and Women's Hospital in Boston, MA. She was a Post-Doctoral Fellow in Oncology at the University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA.
Gralow JR, Biermann JS, Farooki A, Fornier MN, Gagel RF, Kumar RN, Shapiro CL, Shields A, Smith MR, Srinivas S, Van Poznak CH. NCCN Task Force Report: Bone Health in Cancer Care. J Natl Compr Canc Netw 7: Suppl 3:S1-S32, 2009.
Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT, Ravdin P, Bugarini R, Baehner FL, Davidson NE, Sledge GW, Winer EP, Hudis C, Ingle JN, Perez EA, Pritchard KI, Shepherd L, Gralow JR, Yoshizawa C, Allred DC, Osborne CK, Hayes DF. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 11:55-65, 2010
Gralow JR. Adjuvant Systemic Therapy: Bisphosphonates. In Diseases of the Breast, 4th edition, Harris JR, Lippman ME, Morrow M, Osborne CK, ed., Lippincott, Williams & Wilkins, 2009.
Muss HB, Berry DA, Cirrincione CT, Theodoulou M, Mauer AM, Kornblith AB, Partridge AH, Dressler LG, Cohen HJ, Becker HP, Kartcheske PA, Wheeler JD, Perez EA, Wolff AC, Gralow JR, Burstein HJ, Mahmood AA, Magrinat G, Parker BA, Hart RD, Grenier D, Norton L, Hudis CA, Winer EP. Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med 360:2055-2065, 2009.
Koon K, Soldak T, Gralow J. Breast Cancer Advocacy: Changing Perceptions. Salud Publica de Mexico 51: 323-328, 2009.
Fizazi K, Lipton A, Mariette X, Body JJ, Rahim Y, Gralow JR, Gao G, Wu L, Sohn W, Jun S. Randomized Phase II Trial of Denosumab in Patients With Bone Metastases From Prostate Cancer, Breast Cancer, or Other Neoplasms After Intravenous Bisphosphonates. J Clin Oncol 27:1564-71, 2009.
Winer E, Gralow J, Diller L, Karlan B, Loehrer P, Pierce L, Demetri G, Ganz P, Kramer B, Kris M, Markman M, Mayer R, Pfister D, Raghavan D, Ramsey S, Reaman G, Sandler H, Sawaya R, Schuchter L, Sweetenham J, Vahdat L, Schilsky RL. Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening - a report from the American Society of Clinical Oncology. J Clin Oncol 27:812-826, 2009.
Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A, Flockhart DA, Hancock B, Davidson N, Gralow J, Dickler M, Perez EA, Cobleigh M, Shenkier T, Edgerton S, Miller KD. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 26:4672-8, 2008.
Gralow J, Rugo H, Gradishar W, O'Shaughnessy JA, Jahanzeb M, Perez E, Tripathy D. Novel taxane formulations in the treatment of breast cancer: a thought leader discussion and consensus roundtable. Clin Breast Cancer 8:33-7, 2008.
Dunnwald LK, Gralow JR, Ellis GK, Livingston RB, Linden HM, Specht JM, Doot RK, Lawton TJ, Barlow WE, Kurland BF, Schubert EK, Mankoff DA. Tumor Metabolism and Blood Flow Changes by Positron Emission Tomography: Relation to Survival in Patients Treated With Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer. J Clin Oncol 26:4449-4457, 2008.
Gralow JR, Burstein HJ, Wood W, Hortobagyi GN, Gianni L, von Minckwitz G, Buzdar AU, Smith IE, Symmans WF, Singh B, Winer EP. Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol 2008 26(5):814-819.
Gralow JR, Zujewski JA, Winer E. Preoperative therapy in invasive breast cancer: reviewing the state of the science and exploring new research directions. J Clin Oncol 2008 26(5):696-697.
Gralow JR, Tripathy D. Managing Metastatic Bone Pain: The Role of Bisphosphonates. J Pain Symptom Management, 2007.
Gralow J. Bone Density in Breast Cancer: When to Intervene? J Clin Oncol 2007.
Ozols RF, Herbst RS, Colson YL, Gralow J, Bonner J, Curran WJ Jr, Eisenberg BL, Ganz PA, Kramer BS, Kris MG, Markman M, Mayer RJ, Raghavan D, Reaman GH, Sawaya R, Schilsky RL, Schuchter LM, Sweethenham JW, Vahat LT, Winn RJ; American Society of Clinical Oncology. Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening - a report from the American Society of Clinical Oncology. J Clin Oncol 2007 25:146-162.
Gralow JR. Evolving role of bisphosphonates in women undergoing treatment for localized and advanced breast cancer. Clin Breast Cancer 2005.
Gralow JR. Optimizing the treatment for metastatic breast cancer. Breast Cancer Res Treat 2005; 89 Suppl 1:S9-S15.
Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J, Cobleigh MA, Mamounas EP, Goldstein LJ, Whelan TJ, Powles TJ, Bryant J, Perkins C, Perotti J, Braun S, Langer AS, Browman GP, Somerfield MR. ASCO technology assessment on the use of aromatose inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status Report 2004. J Clin Oncol 2004.
Last updated: July 2011